Selected article for: "antiviral activity and current situation"

Author: Servidio, Camilla; Stellacci, Francesco
Title: Therapeutic approaches against coronaviruses acute respiratory syndrome
  • Cord-id: bblbqqbb
  • Document date: 2020_12_30
  • ID: bblbqqbb
    Snippet: Coronaviruses represent global health threat. In this century, they have already caused two epidemics and one serious pandemic. Although, at present, there are no approved drugs and therapies for the treatment and prevention of human coronaviruses, several agents, FDA‐approved, and preclinical, have shown in vitro and/or in vivo antiviral activity. An in‐depth analysis of the current situation leads to the identification of several potential drugs that could have an impact on the fight again
    Document: Coronaviruses represent global health threat. In this century, they have already caused two epidemics and one serious pandemic. Although, at present, there are no approved drugs and therapies for the treatment and prevention of human coronaviruses, several agents, FDA‐approved, and preclinical, have shown in vitro and/or in vivo antiviral activity. An in‐depth analysis of the current situation leads to the identification of several potential drugs that could have an impact on the fight against coronaviruses infections. In this review, we discuss the virology of human coronaviruses highlighting the main biological targets and summarize the current state‐of‐the‐art of possible therapeutic options to inhibit coronaviruses infections. We mostly focus on FDA‐approved and preclinical drugs targeting viral conserved elements.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and lung injury: 1, 2
    • activation essential and lung injury: 1, 2, 3
    • activation essential and lung injury severity: 1
    • adenosine analogue and lung injury: 1
    • adenosine analogue prodrug and lung injury: 1
    • adopt strategy and lung injury: 1
    • low fatality rate and lung injury: 1
    • lung injury and lupus erythematosus: 1, 2